Theralink Technologies, Inc. (THER)
| Market Cap | 6.15K |
| Revenue (ttm) | 635.45K +16.8% |
| Net Income | -13.50M |
| EPS | -0.00 |
| Shares Out | 6.15B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,026,798 |
| Open | 0.000001 |
| Previous Close | 0.000001 |
| Day's Range | 0.000001 - 0.000001 |
| 52-Week Range | 0.000001 - 0.0001 |
| Beta | 59.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Theralink Technologies
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2023, Theralink Technologies's revenue was $606,796, an increase of 6.85% compared to the previous year's $567,905. Losses were -$30.95 million, 138.4% more than in 2022.
Financial StatementsNews
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase ...
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies , Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (rev...
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies , Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein arra...
Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
Golden, Colorado, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay ...
Theralink appoints Faith Zaslavsky as CEO
Theralink Technologies (THER), which in the process of merging with IMAC Holdings, (BACK), announces the appointment of Faith Zaslavsky as its new CEO. Ms. Zaslavsky, who has served as the…
Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay ...
THERALINK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Theralink Technologies, Inc. - THER
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Theralink Tech...
Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University
Company's patent portfolio expands to 10 GOLDEN, Colo. , April 3, 2023 /PRNewswire/ -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a nov...
Theralink® Technologies Begins Receiving Payments from Third Party Payors for its Advanced Breast Cancer Assay, Achieving Key Milestone
GOLDEN, Colo. , Feb. 23, 2023 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for advanced brea...
Theralink's Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative
GOLDEN, Colo. , Jan. 17, 2023 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel quantitative protein and phosphoprotein-based...
Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization
Mr. Vallone's Appointment Supports the Company's Shift from R&D to a Commercially Driven Enterprise GOLDEN, Colo. , Jan. 9, 2023 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or t...
Theralink® Technologies Appoints Seasoned Commercial Leader, Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company
Faith, a Seasoned Genomics Commercial Leader with a Special Interest in Reverse Phase Protein Array Technology and Biomarkers, will Lead Theralink's Commercialization Strategy GOLDEN, Colo. , Dec. 6, ...
Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium
Presented findings highlight the unique insights that Theralink's Assay generates to advance breast cancer research and care GOLDEN, Colo. , Dec. 1, 2022 /PRNewswire/ -- Theralink Technologies (OTC: ...
Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares
GOLDEN, Colo. , Nov. 29, 2022 /PRNewswire/ -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast c...
Theralink® Technologies Achieves the First College of American Pathologists Accreditation for a Commercial Reverse Phase Protein Array Laboratory in U.S.
College of American Pathologists (CAP) Accreditation Signifies the Highest Standards in Laboratory Practice GOLDEN, Colo. , Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralin...
Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment
Important Milestone Toward Enabling Increased Access and Insight for Patients With Advanced Breast Cancer Through Theralink's Precision Oncology Test GOLDEN, Colo. , Nov. 14, 2022 /PRNewswire/ -- Ther...
Theralink® Technologies Appoints Dr. Mattia Cremona as its Director of its Biopharma Laboratory
Seasoned Cancer Research Fellow with specialized interest in Reverse Phase Protein Array Technology to bolster Theralink's management team GOLDEN, Colo. , Nov. 7, 2022 /PRNewswire/ -- Theralink Techn...
Theralink Technologies to Participate in the LD Micro Main Event Conference on October 25-27
Denver, Colorado--(Newsfile Corp. - October 11, 2022) - Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for brea...
Theralink® Technologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14
DENVER , Sept. 7, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a novel, patented phosphoprotein-based assay for breast can...
Theralink® Acquires Two New Milestone Patents Relating to Methods for Treating Breast Cancer
Predictive Biomarker Patents may improve Outcomes for Breast Cancer Patients Patent Portfolio increases to Nine GOLDEN, Colo. , July 25, 2022 /PRNewswire/ -- Theralink Technologies, Inc. (OTC: THER) ...
Theralink® Technologies to Host Fireside Chat with Dr. Mick Ruxin, President and Chief Executive Officer, on June 22nd at 11:00 a.m. ET
DENVER , June 15, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for breast cancer, toda...
Theralink(R) Technologies to Participate in the LD Micro Invitational Conference on June 7-9
Denver, Colorado--(Newsfile Corp. - June 2, 2022) - Theralink Technologies (OTC Pink: THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for bre...
Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
Theralink currently supports preclinical and clinical studies across 11 biopharma clients, including multinational corporations Ongoing discussions with existing clients for development of Companion D...
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
Theralink's RPPA (Reverse Phase Protein Array) Technology to be deployed to support and enhance Genomic insights and may ultimately help improve patient care SIOUX FALLS, S.D. and DENVER, March 28, 20...
Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
DENVER , March 21, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a patented, novel phosphoprotein-based assay for breast ca...